Table 1.

Participant demographic and baseline characteristics as a function of treatment group and gender

	All (n=62)			Female (n=23)			Male (n=39)
	Buspirone (n=35)	Placebo (n=27)	Total (n=62)	Buspirone (n=11)	Placebo (n=12)	Total (n=23)	Buspirone (n=24)	Placebo (n=15)	Total (n=39)
Age, mean (SD), y	44.4 (7.6)	47.3 (6.6)	45.6 (7.3)	41.5 (8.0)	46.8 (5.8)	44.3 (7.3)	45.7 (7.1)	47.7 (7.3)	46.5 (7.2)
Gender, male, n (%)	24 (68.6%)	15 (55.6%)	39 (62.9%)	--	--	--	--	--	--
Race, n (%)
African-American	26 (74.3%)	19 (70.4%)	45 (72.6%)	8 (72.7%)	10 (83.3%)	18 (78.3%)	18 (75.0%)	9 (60.0%)	27 (69.2%)
Caucasian	8 (22.9%)	6 (22.2%)	14 (22.6%)	3 (27.3%)	1 (8.3%)	4 (17.4%)	5 (20.8%)	5 (33.3%)	10 (25.6%)
Other/mixed	1 (2.9%)	2 (7.4%)	3 (4.8%)	0 (0.0%)	1 (8.3%)	1 (4.3%)	1 (4.2%)	1 (6.7%)	2 (5.1%)
Ethnicity, Hispanic, n (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Marital Status, n (%)
Married	3 (8.6%)	5 (18.5%)	8 (12.9%)	2 (18.2%)	1 (8.3%)	3 (13.0%)	1 (4.2%)	4 (26.7%)	5 (12.8%)
Separated/Divorced/Widowed	15 (42.9%)	5 (18.5%)	20 (32.3%)	6 (54.5%)	3 (25.0%)	9 (39.1%)	9 (37.5%)	2 (13.3%)	11 (28.2%)
Never Married	17 (48.6%)	17 (63.0%)	34 (54.8%)	3 (27.3%)	8 (66.7%)	11 (47.8%)	14 (58.3%)	9 (60.0%)	23 (59.0%)
Education, mean (SD), y	11.5 (2.0)	11.8 (1.4)	11.6 (1.8)	10.6 (2.2)	11.6 (1.8)	11.1 (2.0)	11.9 (1.9)	12.0 (1.1)	11.9 (1.6)
Employment, n (%)
Full-time	8 (22.9%)	6 (22.2%)	14 (22.6%)	0 (0.0%)	1 (8.3%)	1 (4.3%)	8 (33.3%)	5 (33.3%)	13 (33.3%)
Part-time	7 (20.0%)	8 (29.6%)	15 (24.2%)	3 (27.3%)	3 (25.0%)	6 (26.1%)	4 (16.7%)	5 (33.3%)	9 (23.1%)
Other	20 (57.1%)	13 (48.1%)	33 (53.2%)	8 (72.7%)	8 (66.7%)	16 (69.6%)	12 (50.0%)	5 (33.3%)	17 (43.6%)
Days/cocaine use 28 days pre-admission	16.4 (8.0)	14.4 (7.1)	15.5 (7.6)	18.6 (8.4)	16.1 (6.5)	17.3 (7.4)	15.4 (7.8)	13.1 (7.4)	14.5 (7.6)

Notes. Where not specifically indicated, numbers represent means (standard deviations).